Trial Profile
A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease requiring initiation of levodopa therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa/entacapone (Primary) ; Levodopa/carbidopa
- Indications Drug-induced dyskinesia; Parkinson's disease
- Focus Adverse reactions
- Acronyms STRIDE-PD
- 17 Feb 2009 Primary endpoint 'Time to disease progression' has not been met.
- 17 Feb 2009 Status changed from active, no longer recruiting to completed, according to an Orion media release.
- 26 Oct 2005 New trial record.